<p>寻找健康相关的长期持有股票的投资者不必再寻找其他地方，这个列表中的股票是医疗保健领域的市场领导者，具有可持续增长、健康的资产负债表、令人印象深刻的价值和广泛的市场支持。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<h2><strong>雅培是长期投资的首选健康股票</strong></h2>
<p>亚利桑那州立大学金融教授亨德里克·贝森拜德的研究发现，<strong>雅培 NYSE: ABT</strong> 是自大萧条以来回报最高的医疗保健股票。他的研究集中在复合回报上，发现雅培是整体回报第 11 高的股票，在医疗保健领域排名第一，年化复合回报率为 13.85%。报告的关键结论是时间的重要性。有些股票可能增长更快，但无法在长期内维持这种速度。雅培是一家经过验证的赢家，专注于长期发展。</p>
<p>雅培的增长轨迹得益于健康的产品组合，包括成熟的制药产品、多样化以及强大的产品管道，确保增长能够持续。2024 年，领先的细分市场是医疗设备，该细分市场在第三季度增长了 11.7%，实现了超预期的季度业绩。诊断和营养细分市场均略有收缩，预计在 2025 财年将恢复增长。包括 COVID-19 和剥离在内的一次性因素影响了诊断和营养细分市场：调整影响后，两者均实现了有机增长。</p>
<p>雅培的资本回报计划包括股息和回购。回购虽然不算强劲，但足以抵消稀释；股息才是关键。雅培的股息在 2024 年将达到 2.20 美元，预计在 2025 年将以低双位数的幅度增长。股息覆盖率充足，派息比率低于 50%，预计收益将增长。资产负债表健康，杠杆率低，现金和资本充足，能够支持产品管道和收购投资。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png"/></p>
<h2><strong>直觉外科是投资者的明智选择</strong></h2>
<h3>直觉外科市场排名™ 股票分析</h3>
<p><strong>整体市场排名™****97 百分位</strong></p>
<p>分析师评级 <strong>适度买入</strong></p>
<p>上涨/下跌 <strong>0.5% 下跌</strong></p>
<p>空头头寸水平 <strong>健康</strong></p>
<p>股息强度 <strong>不适用</strong></p>
<p>环境评分 <strong>-1.15</strong></p>
<p>新闻情绪 **0.78</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI"/></p>
<p>**</p>
<p>内部交易 <strong>出售股份</strong></p>
<p>预计收益增长 <strong>15.65%</strong></p>
<p>查看完整分析</p>
<p><strong>直觉外科 NASDAQ: ISRG</strong> 是医疗技术领域的领先公司。公司的业绩表明，其达芬奇手术机器人在行业中处于领先地位。第三季度的业绩远超竞争对手，收入增长了 17%，得益于强劲的顺风因素。这些顺风因素包括不断扩大的达芬奇平台安装基础、日益增加的批准和不断增长的比较基数。比较基数由扩大的基础、增加的批准和服务的深入渗透驱动，预计这种趋势将持续多年。手术系统简化了手术过程，并为新的应用打开了大门，包括人工智能辅助和远程操作的手术。</p>
<p>直觉外科不向股东返还资本；相反，它选择重新投资于业务并通过增长提供价值。关键细节在于资产负债表，2024 年显示现金增加，各类资产增加，负债稳定，杠杆率极低，股东权益增长 17%。分析师在 2024 年的趋势也积极，情绪被评为适度买入，目标价格上升。MarketBeat.com 报告的共识在 10 月底同比增长 50%，自第三季度报告发布以来增长 15%，修正后目标价格达到 550 到 600 美元的新历史高点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png"/></p>
<h2><strong>联合健康在逆风中持续增长</strong></h2>
<p><strong>联合健康 NYSE: UNH</strong> 面临逆风，包括第一季度的网络攻击和保险业务的医疗成本同比上升。然而，尽管存在这些因素，公司仍在持续增长，得益于不断增加的客户基础和业务量。</p>
<p>2024 年的关键结论是杠杆率和运营质量的提高，这将维持强劲的现金流和健康的资本回报。资本回报包括股息和回购，至少股息每年都在增长。2024 年的股息为 8.40 美元，可靠性低于 30% 的收益，并伴随中位数的十几% 的年复合增长率。回购在第三季度末减少了 0.1% 的股份，并将在 2025 年继续抵消稀释。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png"/></p>
<p>→ 选举警告成真…（来自波特公司）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ"/></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

联合健康

直觉外科

雅培

<p>这篇文章强调了三只值得长期持有的医疗保健股票：雅培、直觉外科和联合健康。雅培因其长期增长和强劲回报而受到关注，特别是在医疗设备领域。直觉外科在医疗科技方面表现出色，其达芬奇手术机器人带来了显著的收入增长。尽管面临挑战，联合健康通过不断扩大的客户基础和可靠的股息保持增长。每家公司都展现了稳健的财务健康和战略性的资本回报，使其成为长期投资者的有吸引力的选择</p>

<p>Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.</p>
<div class="lb-trans"><p>寻找健康相关的长期持有股票的投资者不必再寻找其他地方，这个列表中的股票是医疗保健领域的市场领导者，具有可持续增长、健康的资产负债表、令人印象深刻的价值和广泛的市场支持。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><h2><strong>Abbott Laboratories Is the Number One Health Stock for Long-Term Investment</strong></h2>
<div class="lb-trans"><h2><strong>雅培是长期投资的首选健康股票</strong></h2>
</div><p>study by Arizona State finance professor Hendrik Bessembinder found that <strong>Abbott Laboratories NYSE: ABT</strong> is the top-returning healthcare stock since the Great Depression. His study focused on compound returns, finding Abbott the 11th top-returning stock overall and #1 in healthcare with an annualized compound return of 13.85%. The key takeaway from the report is that time is important. Some stocks may grow faster but cannot sustain the pace over the long term. Abbott is a proven winner, focused on the long term.</p>
<div class="lb-trans"><p>亚利桑那州立大学金融教授亨德里克·贝森拜德的研究发现，<strong>雅培 NYSE: ABT</strong> 是自大萧条以来回报最高的医疗保健股票。他的研究集中在复合回报上，发现雅培是整体回报第 11 高的股票，在医疗保健领域排名第一，年化复合回报率为 13.85%。报告的关键结论是时间的重要性。有些股票可能增长更快，但无法在长期内维持这种速度。雅培是一家经过验证的赢家，专注于长期发展。</p>
</div><p>Abbott’s growth trajectory is sustained by a healthy portfolio that includes established pharmaceuticals, diversification, and a robust pipeline that ensures growth can be sustained. In 2024, the leading segment is Medical Devices, which grew by 11.7% in Q3 to produce a beat-and-raise quarter. Diagnostics and Nutrition both contracted by slim margins, with reported growth expected to resume in F2025. One-offs, including COVID-19 and divestitures, impact the diagnostic and nutrition segments: adjusting for the impact, both are growing organically.</p>
<div class="lb-trans"><p>雅培的增长轨迹得益于健康的产品组合，包括成熟的制药产品、多样化以及强大的产品管道，确保增长能够持续。2024 年，领先的细分市场是医疗设备，该细分市场在第三季度增长了 11.7%，实现了超预期的季度业绩。诊断和营养细分市场均略有收缩，预计在 2025 财年将恢复增长。包括 COVID-19 和剥离在内的一次性因素影响了诊断和营养细分市场：调整影响后，两者均实现了有机增长。</p>
</div><p>Abbott’s capital return program includes dividends and repurchases. The repurchases aren’t robust but sufficient to offset dilution; the dividend is what counts. Abbott’s dividend will be worth $2.20 in 2024 and is expected to grow by a low double-digit amount in 2025. The dividend coverage is ample, with the payout ratio below 50% and earnings forecasted to grow. The balance sheet is healthy, with low leverage and sufficient cash and capitalization to sustain pipeline and acquisitional investment.</p>
<div class="lb-trans"><p>雅培的资本回报计划包括股息和回购。回购虽然不算强劲，但足以抵消稀释；股息才是关键。雅培的股息在 2024 年将达到 2.20 美元，预计在 2025 年将以低双位数的幅度增长。股息覆盖率充足，派息比率低于 50%，预计收益将增长。资产负债表健康，杠杆率低，现金和资本充足，能够支持产品管道和收购投资。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082653_chart-abt-10292024.png"/></p>
<h2><strong>Intuitive Surgical Is an Intuitive Buy for Investors</strong></h2>
<div class="lb-trans"><h2><strong>直觉外科是投资者的明智选择</strong></h2>
</div><h3>Intuitive Surgical MarketRank™ Stock Analysis</h3>
<div class="lb-trans"><h3>直觉外科市场排名™ 股票分析</h3>
</div><p><strong>Overall MarketRank™****97th Percentile</strong></p>
<div class="lb-trans"><p><strong>整体市场排名™****97 百分位</strong></p>
</div><p>Analyst Rating<strong>Moderate Buy</strong></p>
<div class="lb-trans"><p>分析师评级 <strong>适度买入</strong></p>
</div><p>Upside/Downside<strong>0.5% Downside</strong></p>
<div class="lb-trans"><p>上涨/下跌 <strong>0.5% 下跌</strong></p>
</div><p>Short Interest Level<strong>Healthy</strong></p>
<div class="lb-trans"><p>空头头寸水平 <strong>健康</strong></p>
</div><p>Dividend Strength<strong>N/A</strong></p>
<div class="lb-trans"><p>股息强度 <strong>不适用</strong></p>
</div><p>Environmental Score**-1.15**</p>
<div class="lb-trans"><p>环境评分 <strong>-1.15</strong></p>
</div><p>News Sentiment**0.78</p>
<div class="lb-trans"><p>新闻情绪 **0.78</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVNSRyZ2PTI" alt="" original-src="https://www.marketbeat.com/scripts/MediaMentionsMiniChart.ashx?Prefix=NASDAQ&amp;Symbol=ISRG&amp;v=2"/></p>
<p>**</p>
<div class="lb-trans"><p>**</p>
</div><p>Insider Trading<strong>Selling Shares</strong></p>
<div class="lb-trans"><p>内部交易 <strong>出售股份</strong></p>
</div><p>Proj. Earnings Growth<strong>15.65%</strong></p>
<div class="lb-trans"><p>预计收益增长 <strong>15.65%</strong></p>
</div><p>See Full Analysis</p>
<div class="lb-trans"><p>查看完整分析</p>
</div><p><strong>Intuitive Surgical NASDAQ: ISRG</strong> is the leading pure-play on MedTech. The company’s results show that its da Vinci surgical robots lead the field. The Q3 results were head-&amp;-shoulders above the competition, with a 17% increase in revenue driven by strong tailwinds. The tailwinds include an expanding installed base of da Vinci platforms, widening approval, and growing comps. Comps are driven by the expanded base, increased approvals, and deepening penetration of services, which are expected to continue for many years. The surgical systems simplify surgeries and open the door to new applications, including AI assistance and procedures performed from remote locations.</p>
<div class="lb-trans"><p><strong>直觉外科 NASDAQ: ISRG</strong> 是医疗技术领域的领先公司。公司的业绩表明，其达芬奇手术机器人在行业中处于领先地位。第三季度的业绩远超竞争对手，收入增长了 17%，得益于强劲的顺风因素。这些顺风因素包括不断扩大的达芬奇平台安装基础、日益增加的批准和不断增长的比较基数。比较基数由扩大的基础、增加的批准和服务的深入渗透驱动，预计这种趋势将持续多年。手术系统简化了手术过程，并为新的应用打开了大门，包括人工智能辅助和远程操作的手术。</p>
</div><p>Intuitive Surgical does not return capital to shareholders; instead, it chooses to reinvest in the business and provide value with growth. The critical details are in the balance sheet, which 2024 shows increasing cash, increased assets in all categories, steady liability, ultra-low leverage, and a 17% increase in shareholder equity. Analysts' trends in 2024 are also positive, with sentiment pegged at Moderate Buy and the price target increasing. The consensus reported by MarketBeat.com is up 50% YoY in late October, up 15% since the Q3 report was released, with revisions leading to a new all-time high in the $550 to $600 range.</p>
<div class="lb-trans"><p>直觉外科不向股东返还资本；相反，它选择重新投资于业务并通过增长提供价值。关键细节在于资产负债表，2024 年显示现金增加，各类资产增加，负债稳定，杠杆率极低，股东权益增长 17%。分析师在 2024 年的趋势也积极，情绪被评为适度买入，目标价格上升。MarketBeat.com 报告的共识在 10 月底同比增长 50%，自第三季度报告发布以来增长 15%，修正后目标价格达到 550 到 600 美元的新历史高点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082716_chart-isrg-10292024.png"/></p>
<h2><strong>UnitedHealth Group Grows Despite Headwinds</strong></h2>
<div class="lb-trans"><h2><strong>联合健康在逆风中持续增长</strong></h2>
</div><p><strong>UnitedHealth Group NYSE: UNH</strong> has headwinds, including the cyber attack in Q1 and higher YoY medical costs for its insurance business. However, despite those factors, the company is sustaining growth, supported by an increasing client base and volume.</p>
<div class="lb-trans"><p><strong>联合健康 NYSE: UNH</strong> 面临逆风，包括第一季度的网络攻击和保险业务的医疗成本同比上升。然而，尽管存在这些因素，公司仍在持续增长，得益于不断增加的客户基础和业务量。</p>
</div><p>The critical takeaways from 2024 are the increased leverage and operational quality, which will sustain robust cash flow and a healthy capital return. The capital return includes dividends and repurchases, and the dividend, at least, is growing annually. The dividend is worth $8.40 in 2024, is reliable at less than 30% of earnings, and comes with a mid-teens CAGR. The repurchases reduced the count by 0.1% YTD at the end of Q3 and will continue to offset dilution in 2025.</p>
<div class="lb-trans"><p>2024 年的关键结论是杠杆率和运营质量的提高，这将维持强劲的现金流和健康的资本回报。资本回报包括股息和回购，至少股息每年都在增长。2024 年的股息为 8.40 美元，可靠性低于 30% 的收益，并伴随中位数的十几% 的年复合增长率。回购在第三季度末减少了 0.1% 的股份，并将在 2025 年继续抵消稀释。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20241029082707_chart-unh-10292024.png"/></p>
<p>→ Election warning coming true… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 选举警告成真…（来自波特公司）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDAyOQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10029&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Abbott Laboratories right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

这些是适合长期持有投资的顶级健康股票